ReviewProstate cancer and prostatic diseases2010
Bone health and prostate cancer.
Review in Prostate cancer and prostatic diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 59 citations in OpenAlex.
- Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition.BJU international · 2019Trial
- Risk of fracture following androgen receptor pathway inhibitors in men with advanced prostate cancer.Journal of the National Cancer Institute · 2026Article
- Alteration of bone architecture following androgen deprivation therapy in patients with prostate cancer using 3D-modeling from hip DXA.Journal of bone oncology · 2025Article
- Review
- Osteogenic Differentiation Potential of Adipose-Derived Mesenchymal Stem Cells Cultured on Magnesium Oxide/Polycaprolactone Nanofibrous Scaffolds for Improving Bone Tissue Reconstruction.Advanced pharmaceutical bulletin · 2022Article
- Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group.Journal of bone oncology · 2020Article
- Implications of the Fracture Risk Assessment Algorithm for the assessment and improvement of bone health in patients with prostate cancer: A comprehensive review.Turkish journal of urology · 2019Review
- The implications of baseline bone-health assessment at initiation of androgen-deprivation therapy for prostate cancer.BJU international · 2018Article
- [Clinical analysis of bisphosphonate-related osteonecrosis of the jaw].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2016Article
- Automated Detection, Localization, and Classification of Traumatic Vertebral Body Fractures in the Thoracic and Lumbar Spine at CT.Radiology · 2016Article
- Health Resource Utilization Associated with Skeletal-Related Events in Patients with Advanced Prostate Cancer: A European Subgroup Analysis from an Observational, Multinational Study.Journal of clinical medicine · 2014Article
- Novel bone-targeting agents in prostate cancer.Prostate cancer and prostatic diseases · 2014Review
- Androgen-deprivation therapy and risk for biliary disease in men with prostate cancer.European urology · 2014Article
- Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.Inflammopharmacology · 2013Review
- Article
- New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.Prostate cancer and prostatic diseases · 2013Review
- AST-induced bone loss in men with prostate cancer: exercise as a potential countermeasure.Prostate cancer and prostatic diseases · 2012Review
- The Italian cross-sectional survey of the management of bone metastasis: ZeTa study.Journal of bone oncology · 2012Review
- Significant addition to treatment options for bone metastasis in prostate cancer.Cancer biology & therapy · 2012Article
- Fracture risk assessment in Latin America: is Frax an adaptable instrument for the region?Clinical rheumatology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Bone metastases are a substantial burden to men with advanced prostate cancer as they often cause pain and can cause fractures and spinal cord compression. Osteoblasts and osteoclasts are both pathologically activated in the setting of prostate cancer bone metastases. As osteoclast activation is associated with disease progression, skeletal complications and death, osteoclast-targeted therapies are a rational approach to disease management. Zoledronic acid is standard of care for castration-resistant prostate cancer with bone metastases as it reduces the risk for skeletal-related events. Additional trials are needed to better define the ideal dose, frequency and duration of zoledronic acid therapy. No bisphosphonate has yet been shown to prevent bone metastases or to benefit men with androgen-sensitive disease. Denosumab is an experimental osteoclast-targeted monoclonal antibody against receptor activator of nuclear factor-kappaB ligand. Two ongoing phase III trials are expected to define its efficacy in preventing bone metastases and disease-related skeletal events in men with prostate cancer. Androgen-deprivation therapy (ADT) for prostate cancer is associated with osteoporosis and fragility fractures. Several bisphosphonates have been shown to improve bone mineral density in men receiving ADT. Two recent phase III trials have shown that denosumab and toremifene reduce the incidence of fragility fractures in these men. The World Health Organization has developed a fracture risk assessment model (FRAX) for the general population to guide the selection of patients who may benefit from pharmacotherapy. In the absence of a prostate cancer-specific algorithm, we advocate the use of FRAX for men receiving ADT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.